Trump-Backed Biotech Boom: Pharma Giants Unleash Over $225 Billion in New Investments
Former President Donald J. Trump’s push to “Make American Pharmaceuticals Great Again” is gaining major traction, as leading pharmaceutical and biotechnology firms announce a wave of record-breaking investments in U.S.-based operations.
Gilead Leads the Charge with $11 Billion Commitment
Gilead Sciences became the latest industry heavyweight to answer the call for U.S.-centric growth, pledging an additional $11 billion toward its domestic operations. The move reflects growing momentum behind Trump’s emphasis on national security, self-reliance in drug manufacturing, and job creation across the sector.
Massive Commitments from Industry Titans
Gilead is one of several pharma giants making bold moves to align with Trump’s pro-domestic production vision:
-
Johnson & Johnson (NJ): $55 billion investment in U.S. manufacturing, R&D, and tech.
-
Roche (Switzerland): $50 billion into U.S. manufacturing and R&D expansion.
-
Bristol Myers Squibb (NJ): $40 billion dedicated to research, development, and new technologies.
-
Eli Lilly and Co. (IN): $27 billion to double its U.S. manufacturing capacity.
-
Novartis (Switzerland): $23 billion to build or upgrade 10 U.S. manufacturing plants.
-
AbbVie (IL): $10 billion to support volume growth and construct 4 new plants over 10 years.
-
Merck & Co. (NJ): $9 billion investment including a cutting-edge biologics facility in Delaware.
-
Merck Animal Health adds $895 million to expand its Kansas operation.
-
Biotech and Diagnostics Also Surge
-
Regeneron (NY): $3 billion partnership with FUJIFILM Diosynth Biotechnologies to bolster North Carolina production.
-
Amgen (CA): $900 million into Ohio-based manufacturing infrastructure.
-
Abbott Laboratories (IL): $500 million across its Illinois and Texas facilities.
Trump’s Vision: Jobs, Security, and Sovereignty
The surge in domestic investment signals a major win for Trump’s economic and industrial agenda, reinforcing the United States’ capacity to manufacture critical medicines and biotech products at home — a move framed as essential for both national security and economic revitalization.
“America must never be dependent on foreign nations for life-saving drugs or technologies,” Trump has repeatedly stated. “We are rebuilding our industries, our factories, and our workforce — and this is just the beginning.”
Kosta Gushterov
Reporter at Coindoo
Kosta has been a part of the team since 2021 and has solidified his position with a thirst for knowledge, incredible dedication to his work and a “detective-like” mindset. He not only covers a wide range of trending topics, he also creates reviews, PR articles and educational content. His work has also been referenced by other news outlets.
